معرفی
Harry Al-Wassiti is a Research Fellow in Drug Delivery Disposition & Dynamics at Monash University. He serves as Primary Chief Investigator on multiple research projects focused on mRNA vaccine development and delivery systems, and is an active member of the Monash RNA expert group.
His research interests span several key areas in pharmaceutical sciences and vaccine development:
- mRNA vaccine technology and manufacturing
- Lipid nanoparticle delivery systems
- SARS-CoV-2 variants and immune responses
- Novel vaccine formulations to overcome immune imprinting
- Gene delivery mechanisms for therapeutic applications
- PEG-lipid alternatives for mRNA stabilization
Dr. Al-Wassiti's recent publications demonstrate a strong focus on advancing mRNA vaccine technology, particularly in developing more effective delivery systems and understanding immune responses. His work bridges fundamental pharmaceutical science with practical vaccine development applications, contributing significantly to pandemic preparedness and response. His research shows particular expertise in how mRNA delivery to lymphoid organs drives immune responses and how membrane-anchored receptor-binding domains can overcome immune imprinting.
He has been recognized for his expertise through multiple media contributions in 2021 discussing mRNA vaccine technology, including commentary on vaccine rollout strategies and scientific principles behind mRNA vaccines. His work has been cited in numerous academic publications with several papers receiving double-digit Scopus citations.
Dr. Al-Wassiti leads or co-leads several major research initiatives:
- Next-generation mRNA manufacturing and analysis technologies (2024-2027)
- Development of novel mRNA products for clinical trials (2023-2028)
- RaRtech: rapid mRNA manufacturing technology for pandemics (2022-2025)
- Designing non-viral gene delivery system based on adenovirus core (2016-2018)
